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Summary 
After the cloning of murine cytokine synthesis inhibitory factor, it was recognized that a homol- 
ogous open reading frame was encoded within the Epstein-Barr virus (human  herpes virus 4). 
This viral protein has now been termed viral interleukin 10 (vlL-10) to reflect its protein sequence 
homology to "cellular" Ibl0 (clbl0, either murine or human Ibl0).  It is now widely accepted 
that  vlL-10  shares  many functions with  clL-10,  principally,  the  ability to enhance  survival of 
newly infected B cells and to diminish  the production of IFN-~ and II.-2 during ongoing im- 
mune reactions.  The immunomodulatory effect of locally secreted vlbl0 and murine Ibl0 (mlbl0) 
was examined in  tumor  models using CL8-1  (a BL6 melanoma cell line transfected with  the 
H-2K  b class  I  gene)  in  syngeneic  animals.  Although  parental  BL6 tumor  cells  grow  in  im- 
munocompetent  syngeneic hosts,  CL8-1  are rejected.  To achieve local secretion of vlL-10,  we 
generated vlbl0 retroviral vectors. While nontransduced  CL8-1 cells (1  x  104) failed to grow 
when injected intradermally  in C57BL/6  mice,  CL8-1 cells (1  x  104) transduced with vlL-10 
formed palpable tumors  and eventually killed 80%  of injected animals.  Suppression of tumor 
rejection was also noted when CL8-1 tumors with or without vlL-10 transfection were admixed 
with syngeneic vlL-10-transfected fibroblasts and inoculated.  Since the in vitro proliferation of 
the tumor was not altered after transduction with the vlL-10 gene and injection of vlD10--trans- 
duced CL8-1 does not affect the rejection of nontransduced  CL8-1 inoculated at a distant  site, 
local vlL-10 secretion appears to suppress the process of immune rejection of the target cells in 
a dose-dependent manner.  Similar results were observed for the H-2  b MCA105 sarcoma tumor 
model in  allogeneic BALB/c mice (H-2d).  Although  all animals  that  received nontransfected 
MCA105 rapidly rejected these tumors, MCA105 sarcomas transfected with vlL-10 remained pal- 
pable for up to 37 d. The local immunosuppressive effect of gene-delivered vlL-10 could be neu- 
tralized by anti-human  II.-10 monoclonal antibody or could be reversed by the systemic adminis- 
tration of II.-2 or Ib12. In marked contrast, mlL-10 transfection of CL8-1 significantly suppressed 
tumor growth  and frequently led to the rejection of tumor.  Similar results were obtained for 
the murine tumor cell lines MC38 and MCA102. These results contrast the immunologic effects 
of vlL-10 and clL-10 and argue for divergence in the function of the vitally captured gene, which 
is presumably the result of altered interaction with one of the two derived II.-10 receptors. The 
present study, along with our recent study showing prolonged survival of cardiac allografts trans- 
duced with retroviral vlL-10,  suggests that local vIL-10, but not mIL-10,  secretion can suppress 
immune  reactivity in both  the  syngeneic and allogeneic  settings. 
T 
he  cytokine  Ibl0  was  initially  described  as  cytokine 
synthesis inhibitory factor (CSIF),I a product of mouse 
1 Abbreviations  used in thispaper: CHO, Chinese hamster ovary; ci1"10, cel- 
lular 11"10; CSIF, cytokine  synthesis inhibitory factor; hlbl0, human ID 
10; MCA, methylcholanthrene; mi1"10, murine II,10; vi1,10; viral I1.-10. 
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Th2 cells that inhibited cytokine synthesis of Thl cells (1). 
The CSIF activity of IL-10 is mediated principally via its in- 
hibitory effects on APC and accessory cell function by mac- 
rophages and dendritic ceils (2, 3). Murine "cellular" Ibl0 
(raiL-10) and human cellular 11.-10 (hlbl0) cDNA sequences 
exhibited a strong homology to a previously uncharacterized 
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IL-10 (vlL-10), formerly termed Barn H1, C fragment right- 
ward reading frame 1 (4,  5). The hlLol0 and vlL-10 mature 
protein sequences are 84% identical, with most of their diver- 
gence found in the NH2-terminal 20 amino acids (4).  The 
vlbl0 gene was initially characterized as a "late" viral gene, 
expressed during the lyric phase of virus replication (6), but, 
more recently, vlL-10 has been suggested to be an immediate 
early gene product (7). The protein product of vlL-10 shares 
some functional properties with both hIL-10 and mIL-10 (5). 
vIL-10 shares  many functions of cellular IL-10 (cIL-10) and 
mediates predominantly immunosuppressive effects through 
the inhibition of  cytokine synthesis (II,2 and IFN-3') by human 
PBMC  (1,  8,  9).  vIL-10 strongly reduces  antigen-specific 
human T  cell proliferation by diminishing the antigen-pre- 
senting capacity of monocytes via down-regulation of class 
II MHC expression (10). However, vIL-10  does not (a) costimu- 
late the proliferation of murine thymocytes (11), (b) stimu- 
late proliferation of murine mast cell lines (5, 12), or (c) in- 
duce increased expression of  class II MHC molecules on murine 
B cells (13). Thus, vIL-10 appears to function as a predomi- 
nantly immunosuppressive agent. These in vitro results sug- 
gest that vIL-10 could be an ideal cytokine for blunting the 
immune response after transplantation or potentially in the 
setting of autoimmune disease. 
To test this hypothesis, we used a tumor system that directly 
reflects the in vivo immunologic environment. Some tumors 
in experimental animals escape T  cell-mediated destruction 
by down-regulation of MHC class I molecule expression (14). 
The  importance  of these molecules in  tumor  rejection is 
strongly supported by experiments in which transfection of 
class I MHC gene(s)  leads to restoration of tumor cell im- 
munogenicity and prevention of tumor growth in an im- 
munocompetent host (15, 16). Although the B16 melanoma 
expresses low levels of H-2 class I molecules and is poorly 
immunogenic (17, 18), transfection of B16 melanoma cells 
with H-2K  b results in increased  immunogenicity and rejec- 
tion (19). We used retrovirus-mediated gene transfer to in- 
troduce the vIL-10 and mIL-10 genes into these ceils, and we 
studied the consequences  of local cytokine production on the 
development of tumors in vivo. The results distinguish the 
effects of vIL-10 and cIL-10 in vivo and support in vitro evi- 
dence suggesting that vIL-10 is able to confer only a subset 
of the activities of the cIL-10. The present results, along with 
our recent study showing prolonged survival  of cardiac al- 
lografts after retrovirus-mediated vIL-10 transduction (Qin, 
L., unpublished observation), indicate that local vIL-10 but 
not mIL-10 production can suppress immune responses in both 
syngeneic and allogeneic settings. 
Materials and Methods 
Mice.  Female  C57BL/6 mice and BALB/c mice, 8-12 wk old, 
were obtained from The Jackson Laboratory (Bar Harbor, ME). 
Mice were routinely screened and found to be pathogen free. 
Murine Cell Lines.  The CL8-1 clone was generously provided 
by Dr. E. Gorelik (University of Pittsburgh,  Pittsburgh, PA) and 
used in most experiments. CL8-1 (19) was obtained after cotrans- 
fection of the BL6-8 (H-2K  b-,  H-2D ~§  B16 melanoma clone 
with a plasmid encoding the class I gene H-2K  b and one encoding 
the bacterial neomycin phosphotransferase gene conferring sensi- 
tivity to the neomycin analogue, Geneticin (G418; GIBCO BRL, 
Gaithersburg, MD). MCA102  and MCA105 are methylcholanthrene 
(MCA)-induced murine fibrosarcomas. MC38 is a routine colon 
adenocarcinoma  cell  line. All were generously  provided  by Dr. S. A. 
Rosenberg (National  Cancer Institute, National Institutes of  Health, 
Bethesda, MD) and maintained by serial transplantation in mice 
(20). Tumor cell lines were maintained as adherent cultures derived 
from harvesting  fresh tumor specimens *10 mm in diameter.  TIB81 
is an H-2  b embryonic fibroblast cell line purchased from Amer- 
ican Type  Culture Collection (Rockville, MD). CL8-1, MCA102, 
MCA105, and MC38 ceils  were maintained  in RPMI 1640 (GIBCO 
BRL) supplemented  with 10% heat-inactivated  FCS, 2 mM L-gluta- 
mine, 100 IU/ml penicillin, and 100/xg/ml streptomycin. TIB81 
cells were maintained  in DMEM (GIBCO BRL) supplemented  with 
10%o FCS, 2 mM t-glutamine, 1 mM sodium pyruvate, 0.1 mM 
nonessential amino acids, 100 U/ml penicilLin,  and 100 mg/ml strep- 
tomycin. 
Reagents.  rhIL-2  was obtained from Dr.  A.  Louie (Chiron, 
Emeryville, CA) and had a specific activity of 18  x  106 IU/mg 
(21, 22). Recombinant murine IL-12 (rmIL-12) was kindly provided 
by Dr.  B.  Hubbard (Genetics Institute,  Cambridge, MA). The 
specific activity was 5-7  x  106 U/mg as determined in a PHA 
blast proliferation assay as previously described (23). For in vivo 
administration, IIA2 was diluted in 0.1% mouse albumin carrier 
protein, mAb  19F1, which blocks both hIL-10 and vIL-10, was 
provided by Schering-Plough  Research Institute (Kenilworth, NJ). 
Construction of Vectors Carrying rill0 and raiL,10.  The cDNA- 
encoding  vIL-10  and mIL-10  were subcloned  into a retroviral-proviral 
construct termed MFG (4, 24, 25). The cDNAs were inserted into 
MFG so that the translational initiation codon ATG of vIL-10 and 
mIL-10 protein was fused to the ATG of the retroviral env gene. 
We have also subdoned vIIA0 and mIL-10  cDNA into a modified 
MFG (termed DFG), which simultaneously expresses a neomycin 
transferase gene as a selectable  marker (26) (Fig. 1). The packaging 
cell line termed ~CRIP (27) was transfected with these proviral 
plasmids using the calcium phosphate method to generate stable 
producer cell lines. 
Figure 1.  Structure  of retroviral constructs containing  cDNAs of vile 
10 and mlL-10.  (A) MFG-mlL-10,  and (/3) MFG-vlL-10.  vlL-10 and mlbl0 
cDNAs were subcloned  into the Nco 1 cloning  site, which  allows  fusion 
of the protein-coding  region of the cloned  gene into the ATG of the env- 
coding  region. Both  vlL-10 and mlL-10  are expressed  with a spliced RNA 
message.  (C) DFG-mlIA0-Neo,  and (D) DFGwlL-10-Neo.  vlL-10  and mlL-10 
cDNAs were  subcloned  into DFG-Neo. Neomycin  transferase  can be trans- 
lated because of an internal  ribosome  entry site (IRES), located  5' to the 
Neo cDNA insert.  LTR, long  terminal  repeat; a/, r  sequences; 
SD, splice donor; SA, splice acceptor. 
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or fibroblast cell lines were infected in culture using viral superna- 
tant from the respective producer cell lines. Cells were incubated 
with viral supernatant  containing  polybrene (8/~g/ml) at 37~ 
for 3 h. After incubation, viral supematant was replaced with fresh 
medium. When the cells were infected with DFG, cells were split 
48 h after the infection and selected in media containing 0.5-0.75 
/~g/ml G418. Supernatant of infected cells was harvested after in- 
fection and tested for vlL-10 and mlbl0 protein using an ELISA 
as directed (Pharmingen, San Diego, CA). The amount of vlL-10 
was determined with an ELISA, which detects both v- and hlL-10 
but does not cross-react with mlL-10. Levels  of mlL-10 were mea- 
sured by ELISA using an mAb specific to mlL-10. 
In Vivo Cell Proliferation Assay.  Morphology and in vitro cell 
proliferation patterns were compared between vlbl0- and mlbl0- 
transduced and nontransduced tumors (CL8-1, MCA105, MC38). 
1 x  10  s nontransduced vlbl0-transduced, and mlL-10-transduced 
cells were seeded into 10-cm dishes. At certain time points (1, 2, 
3, 4, and 5 d after the cell split), the morphology of  cells was exam- 
ined, and the number of total cells in each dish was evaluated after 
obtaining  single cell suspensions by trypsinization. 
Murine Studies.  The mice used in the experiments were ear 
tagged and randomized before inoculation with tumor. Tumor cells 
were inoculated intradermally in the shaved area of the left flank, 
and tumor establishment was determined by palpation. Tumor size 
was determined by measuring perpendicular tumor diameters with 
a vernier caliper. In some experiments, tumor cells were injected 
intradermally admixed with fibroblasts. All these measurements 
were done in a coded, blinded fashion. Systemic rhlL-2, rmlL-12, 
and anti-hlL-10 mAb were administered by intraperitoneal injec- 
tion.  Treatment groups  consisted of five mice per group. 
Immunohistockemistry.  Tumor specimens were harvested  and snap 
frozen 10 d after nontransfected CL8-1, CL8-1-vlL-10, or CL8-1- 
mlbl0 cells were inoculated into syngeneic mice. Cryostat-cut sec- 
tions were fixed in cold acetone, hydrated in PBS, and incubated 
in protein-blocking solution (Lipshaw Immunon, Pittsburgh,  PA) 
for 8 min.  They were then incubated overnight at 4~  with rat 
mAbs  directed  against mouse  CD4,  CD8,  and  macrophages 
(MOMA-2; Serotec Ltd., Oxon, UK.) Isotype-matched rat IgG 
was used as a negative control. A biotinylated mouse primary anti- 
body against I-A  b was also used. In this case, an irrelevant biotin- 
ylated mouse mAb (anti-BRDU; Caltag Laboratories, San Fran- 
cisco, CA) was used as a negative control. Positive tissue controls 
consisted of frozen sections of spleens from B10 and BALB/c mice. 
After buffer washes, endogenous peroxidase activity was quenched 
with  0.6%  H202  in  methanol.  Species-absorbed biotinylated 
mouse  anti-rat  F(ab')2 (Jackson ImmunoResearch  Laboratories, 
Inc., West Grove, PA) was applied to sections incubated with unla- 
beled primary antibodies, followed  by streptavidin peroxidase  (Boeh- 
ringer Mannheim, Indianapolis, IN) and 3'-amino-9-ethylcarbazole 
(Biomeda Corp.,  Foster City, CA).  In the case of anti-I-A b and 
its negative control, the biotinylated secondary antibody was elim- 
inated. Sections  were counterstained with hematoxylin and mounted 
in Crystal Mount (Biomeda Corp.). 
Statistical Analysis.  The percentage of mice with tumor and 
tumor size in each group were calculated and compared with other 
groups using a standard Student's t test. The differences  were con- 
sidered statistically significant when the P value was <0.05. 
Results 
Substantial Amounts of v lb l O  and mlL-l O  Proteins Are Secreted 
after Infection of Cells with Retroviral  Vectors.  The levels of 
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v- and mlL-10 secreted from target cells infected with retrovirus 
are shown in Table 1. These levels from infected cells were 
higher than those from COS-7 ceils transfected with an ex- 
pression plasmid (pJJRU3-vIbl0), which has a modified SV40 
promoter (28) to drive vIIr  gene expression (COS-7, 3.2 
ng/106 cells  per 48  h).  Repeated infections have often in- 
creased expression of IL-10 protein. No significant difference 
in cell proliferation (Fig. 2) or H-2K  b expression (mAb 28- 
13-3S,  anti-H-2K  b,  IgM;  American Type Culture Collec- 
tion) was observed when compared with nontransduced CL8-1 
and CL8-1-vIL-10  cells. 
In Vivo Growth of  Nontransfected Tumor Cells in the Syngeneic 
or Allogeneic  Setting Is  Tumor Dose Dependent, and Rejection 
Is Mediated Immunologically.  Class I-transfected CL8-1 ceils 
have been reported to grow less well when compared with 
parental BL6 melanoma cells in an immunocompetent syn- 
geneic host (19, 29). Titered doses of CL8-1 cells and BL6 
cells were inoculated intradermally into syngeneic mice to 
confirm this difference (C57BL/6, groups of five mice; data 
not shown). Parental BL6 cells grew as intradermal tumors 
in all mice, even when as few as 1  x  104 cells were inocu- 
lated. At the same cell dose, CL8-1 was poorly tumorigenic, 
inducing tumors in no more than 0-20% of mice. Only when 
>1  x  105  CL8-1 cells  were inoculated intradermally into 
syngeneic mice did 60-80%  of the animals develop a pal- 
pable  tumor.  Expression  of the  class  I  gene  (H-2K  b)  in 
tumor cells is associated  with a reduced tumorigenic poten- 
tial in syngeneic recipients. In an allogeneic setting (H-2  d, 
BALB/c; data not shown), all tumors were rejected within 
2-3 wk after inoculation. 
To examine the mechanism of rejection of the CL8-1 cells 
in syngeneic animals, varying doses of CL8-1 cells were in- 
oculated intradermally into irradiated (a  sublethal dose of 
500 g  to whole body) or nonirradiated C57BL/6 mice (Fig. 
3, A  and D). While I  x  104 CL8-1 cells did not grow in 
nonirradiated immunocompetent mice, they did grow in all 
of the irradiated mice. The size of the tumor at day 25 in 
irradiated mice  (1  x  104, 19.40  _+  4.67 mm2;  5  x  104, 
36.40  _+  9.50 ram2; 1  x  10  s, 56.20  __  8.77 mm  2) was fig- 
nificantly larger than that observed in CL8-nonirradiated mice 
(1  x  104, 0  _  0 ram2;  5  x  104, 2.40  _+  5.37 ram2;  1  x 
10  s, 9.60  _+  9.21 ram2; P <0.0001). Thus, failure of tumor 
growth appears to be mediated by radiation-sensitive, most 
likely immune,  cells. 
rill0  Gene Transduction Can Suppress Immune Rejection of 
Tumor Cells In Vim  A series of experiments was performed 
to determine if local rib10 secretion could suppress immune- 
mediated rejection of CL8-1 tumor cells inoculated intrader- 
mally into syngeneic animals.  104 CL8-1 cells,  transduced 
with  MFG-vlL-10  (CL8-1-vlL-10,  72.56  ng/106  cells  per 
48 h), were injected intradermally into syngeneic C57BL/6 
animals.  Although nontransduced CL8-1 cells failed to grow 
in any of these animals, CL8-1-vIL-10 displayed palpable tumors 
in 80% of injected animals. All of these animals developed 
progressively growing tumors (Fig.  3, B and E). The size 
of the CL8-1-vIbl0 tumors at day 35 (89.6  _+  67.7 mm  2) 
was significantly larger than that of nontransfected CL8-1 
tumors (0  +-  0 mm  2, P  =  0.018). All of the animals inoc- Table  1.  Expression  of vlL-lO and mlL-lO Proteins After  Transfection 
Mean  +  SD 
Cells  Cell type  Vector  Selection*  (experiment No.)* 
ng/106  cells per 48  h 
3T3  Fibroblast  MFG-vlL-10  -  30.62  +  7.45  (5) 
DFG-vlL-10-Neo  +b  106.83  _+  37.52  (5) 
MFG-mlL-10  -  37.09  +_  12.6  (2) 
DFG-mlL-10-Neo  + b  55.50  (1) 
TIB81  Fibroblast  MFG-vlL-10  -  16.72  (1) 
DFG-vlL-10-Neo  +b  32.59  _+  7.45  (11) 
DFG-mlL-10-Neo  +b  36.70  +  8.63  (2) 
CL8-1  Melanoma  MFG-vlL-10(x 1)  S  -  21.49  +  8.21  (21) 
(x 2)  -  43.56  _+  12.50  (13) 
(x 4)  -  61.73  +  12.24  (7) 
DFG-vlL-10-Neo  -  78.47  +  30.03  (7) 
MFG-mlL-10  -  42.06  +  9.65  (4) 
Re-CL8-1 II  Melanoma  MFG-vlL-10(lw)  -  62.8  (1) 
(2w)  -  54.9  (1) 
(4w)  -  25.4  (1) 
MCA105  Sarcoma  MFG-vlL-10  -  26.80  _+  6.05  (4) 
DFG-vlL-10-Neo  +b  67.55  _+  18.76  (12) 
MCA102  Sarcoma  DFG-mlL-10-Neo  +b  38.12  _+  20.62  (3) 
MC38  Colon cancer  DFG-vlL-10-Neo  +b  57.71  +  13.12  (7) 
DFG-mlL-10-Neo  +b  45.31  _+  17.37  (3) 
COS-7  Epithelial cell  pJJRU3-vlL-101  -t  3.20  (1) 
* +, selected with G418; -,  not selected; b, bulk, G418-resistant cells without an attempt  of cell cloning;  t, transient expression of vlL-10. 
Levels of the vll-10 and mll-10  secretions were determined in the supernatant of cell cultures. 
S Repeat infection. 
II Re-CLS-I-vlL-10:CL8-1-vlL-10  cells were inoculated intradermally, harvested from resultant tumors (1.0-cm diameter) 4 wk after the inocula- 
tion, and introduced  to cell culture again. Secretion of vlL-10 was tested on the supernatant of the cell culture at  1,  2,  and 4 wk in culture. 
Cells were  transduced with calcium phosphate transfection. 
ulated  with  5  x  104  CL8-1-vlL-10  cells  had  progressive 
tumor growth,  and the size of the tumors at day 35 (180.4 
+_  72.5 mm  2) was significantly larger than that observed in 
nontransfected  CL8-1  tumors  (20.0  +  44.7  mm 2,  P  -- 
0.003). 
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Figure  2.  CL8-1  cell growth in culture was not altered after transduc- 
tion with either vlL-10 or mlL-10. Cells were counted daily using trypan 
blue exclusion to identify viable cells. 
To determine if transduced fibroblasts could also be used 
to deliver vlL-10 at the site of tumor cells, CL8-1 or CL8-1- 
vlL-10 was admixed with TIB81 fibroblasts, which were trans- 
duced with both vlL-10 and Neo (TIB81-vlL-10) or Neo only 
(TIB81-Neo; Fig. 3, C  and F).  1  x  105 TIB81-vlL-10 (27.0 
ng/106  cells per  48  h)  or  TIB81-Neo  cells were  admixed 
with  1  x  104 CL8-1-vlL-10 (25.2 rig/106 cells per 48 h) or 
nontransduced CL8-1  cells, and were injected into the left 
flank of C57BL/6  mice.  All mice  rejected nontransduced 
CL8-1  tumor cells admixed with TIB81-Neo within  14 d, 
while 40% of CL8-1-vlL-10 admixed with TIB81-Neo formed 
palpable growing tumors. Rejection of nontransduced CL8-1 
cells was also inhibited by admixed TIB81ovlL-10 cells at a 
fibroblast/tumor ratio of 10:1. The size of the nontransfected 
CL8-1  admixed with  TIB81-Neo  tumors  at  day 35  (0  _+ 
0  mm  2) was smaller when compared with those of animals 
receiving CL8-1-vlL-10 admixed with TIB81-vlL-10 tumors 
(75.0  _+  51.7  mm  2,  P  =  0.012),  CL8-1-vlL-10  admixed 
with TIB81-Neo  tumors  (19.2  _+  26.9  mm  z, P  -  0.149), 
or nontransfected CL8-1 admixed with TIB81-Neo (9.4  _+ 
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Figure 3.  vlL-10  promotes CL8-1 tumorige- 
nicity. Tumor growth was examined twice or 
thrice weekly. Shown are percentages of ani- 
mals with tumor (A-C) and mean tumor area 
(D-F). (A and/9) Rejection of CL8-1 was 
abrogated by total body radiation. Irradiated 
C57BL/6 mice (five  per group) or nonirradi- 
ated C57BL/6 control mice (five per group) 
were injected  intradermally  with varying  doses 
of CLf-1 cells on the left flank. (O), 1 x  104 
CL8-1 cells were injected into irradiated mice; 
(A) 5  x  104 CLf-1  cells were injected in 
irradiated mice; (D)  1  x  los  CLf-1  cells 
were injected in irradiated mice; (0) 1 x  104 
cells were injected  in controls; (A) 5  x  104 cells 
were injected in controls; (11) 1 x  10  s cells 
were injected in controls. (B and E) Effect of 
vlbl0 on CL8-1 tumor growth. C57BL/6 mice 
(five  per group) were injected intradermaUy  in 
the left flank with 1 ￿  104 or 5  x  10  4 non- 
transfected  CL8-1 cells (controls)  or CL8-1-vIb 
10 cells. (O) 5 x  10  4 CLf-l-v-Ibl0; (A) 1 x 
104 CL8-1-vIB10; (0) 5  x  10  4 CL8-1; (A) 1 
x  104 CLf-1. (C and F) Tumor progression 
can be promoted using coadministration of the TIB81-vlL-10  fibroblast with tumor. C57BL/6 mice (five per group) were injected intradermally in 
the left flank with I  x  104 CLf-I-vlL-10  or nontransfected  CL8-1 cells admixed with I  x  los TIB81-vlL-10 or TIB81-Neo fibroblasts. (O) CL8-1-vlL- 
10  +  TIB81-vlL-10;  (A) CL8-1-vlbl0  +  TIB81-Neo; (/-]) CL8-1 +  TIB81-Neo; (X) CL8-1 +  TIB81-vlL-10. 
21.0  mm 2,  P  =  0.347).  Furthermore,  addition  of vlL- 
10-transfected  TIB81 cells in the tumor inoculum further 
suppressed the rejection of CL8-1-vlL-10 tumor.  Thus,  im- 
munosuppressive effects were also observed when vii.-10 was 
delivered in the tumor  environment  by fibroblasts. 
Similar results were also observed in an allogeneic setting 
in  which  tumor  is  normally  rejected  rapidly.  MCA105 
(H-2b), transduced with DFG-vlLq0 and selected for Neo 
resistance  (MCA105-vlL-10,  83.42  ng/106  cells  per 48 h), 
were injected into allogeneic animals  (BALB/c, H-2a).  Al- 
though all of the animals that received nontransfected  MCA105 
rejected the tumor by 14 d after injection,  MCA105-vlL-10 
remained palpable for up to 37 d (Fig. 4, A  and B). While 
all of the vlL-10-transfected tumors were eventually rejected, 
this process was significantly delayed (mean  _+ SD =  23.2  + 
11.7 d) when compared with nontransduced MCA105 tumors 
(6.4  +  6.2 d, P  =  0.022).  These results indicate that local 
vlbl0 secretion can suppress immune rejection of both syn- 
geneic and allogeneic tumors. 
To examine the in vivo expression of the transduced vlL-10 
gene in progressively growing tumors, CLf-I-vlL10 cells were 
inoculated intradermally,  harvested from resultant tumors (1.0 
cm diameter) 4 wk after the inoculation, and cultured in vitro 
(Re-CL8-1-vlL-10). The secretion of vlbl0 in culture super- 
natant  was examined by ELISA.  R.e-CL8-1-vlL-10  cells ex- 
pressed vlbl0 protein at  the level of 25.4 ng/10 6 cells per 
48 h for up to 4 wk after harvest (Table 1). Class I expression 
of Re-CL8-1-vlL-10 was  also  examined  using  anti-H-2K b 
and flow cytometry. The level of the class I expression was 
not altered (data not shown). Although we did not evaluate 
the expression of IL-10 in rejecting tumors, which is opera- 
tionally difficult to perform in tumors that  are only barely 
palpable during the first 10 d after inoculation, we have shown 
that ILl0 effects are abrogated  by irradiation (data not shown) 
and that  the rib10,  mlL-10,  and wild-type animal tumors 
had very different immunohistochemical patterns at 10 d (see 
below). Although technically possible, the use of in situ hy- 
bridization techniques, RT-PCR, and immunohistochemistry 
to detect mlL-10 (or vlL-10) protein or messenger RNA in 
vivo would only allow demonstration  of gross differences, 
and these methods were considered to be far less  sensitive 
than  the ELISA performed in vitro before inoculation. 
The Local Secretion of vlLlO Does Not Affect Rejection of a 
Nontransduced Tumor at a Distant Site.  To examine whether 
locally secreted vlL-10 protein also has systemic effects,  1  x 
104 nontransduced  CL8-1  cells  were injected in  the  right 
flank of C57BL/6, and 1  x  104 CLf-I-vlI~10 (42.3 ng/106 
cells per 48 h, group 1) or nontransduced CLf-1 cells (group 
2) were injected in the left flank concurrently (Fig.  5, A  and 
D). All animals in group 2 rejected the tumor in both sides. 
1  I~)  B 
o- 
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Figure  4.  Paracrine vlb10 secretion suppresses allorejection  of  MCAI05 
sarcoma (H-2  b) in BALB/c (H-2  a) mice. BALB/c mice (five per group) 
were injected intradermally into the left flank with 1  x  los MCA105- 
vlL-10 or wild-type MCA105 cells. Tumor growth was assessed two or 
three times per week. (O) MCA105-vlL-10; (@) MCA105. 
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Figure 5.  Local  secretion  of vlL-10  does not 
affect rejection of nontransfected tumor at a 
distant site, and immune-suppressive  effects  can 
be overcome  by administration of antibody to 
IL-10 or by administration of systemic II.~2 or 
I1.-12. (tt  and D) C57BL/6  mice (five per 
group) were injected intradermally in the left 
flank with  1  ￿  104 nontransfected CL8-1 
cells. Mice  were concurrently  injected  intrader- 
mally in the right flank with I  x  104 CLS-1- 
vlL-10 or I  x  104 nontransfected CL8-1. (O) 
group 1, right  flank with CL8-1-vlD10; @, 
group 1, left flank with CL8-1; (1-1) group 2, 
right flank with CL8-1; (,) group 2, left flank 
with CL8-1. The effects  of vlL-10 transfection 
can be reversed  by IL-2  or II:12 administration. 
(B and E) C57BL/6 mice were inoculated in- 
tradermally in the left flank with 5  x  104 
CL8-1-vlL10  or nontransfected  CL8-1 cells on 
day 0. On days 7-13, Hanks' solution (1.0 ml), 
600,000 ILl of systemic rhlb2, or 0.1 mg of 
systemic  rmlL-12 was  administered  in- 
traperitoneally once daily. (O) CLS-I-vlL-10; 
(X)  CL8-1-vlD10 +  Hanks'  solution; (V]) 
CL8-1-vlL10 +  Ib2; A, CL8-1-vlL-10 +  IL-12.  The immunosuppressive  effect of vlL-10 can be blocked by the administration of antibody to vlL-10. 
(C and F) Anti-vlbl0 mAb (0.5 mg per mouse) was administrated as intraperitoneal injections 24 h before tumor inoculation and on day 7. C57BL/6 
mice were inoculated intradermally in left flank with 1 ￿  104 CL8-1-vlD10 or nontransfected CL8-1 cells on day 1. (O) CL8-1; (A) CLS-I-vlL-IO; 
([3) CLS-I-vlD10 +  anti-hlL-10 mAb. 
In group 1, 60% of the animals developed CL8-1-vlL-10 tumors 
in the left flank within  7 d  (day 44,  group 1:78.0  +  72.5 
mm z vs  group  2:0  +-  0  mm  2,  P  =  0.043)  and  died of 
progressive tumor, but none of the animals developed a pal- 
pable tumor in the right  flank.  These results suggest  that 
local secretion of vlL-10 pr3tein suppressed tumor rejection 
at that site but did not affect the immune-mediated rejection 
of nontransduced tumors at a distant site. They also suggest 
that tumor-reactive T  cells primed at a distal site do not im- 
pact on the progression of vlL-10 tumors. 
The Immunosuppressive Effects of vlL10 Can Be Reversed by 
the Administration of  Anti-vlLlO Antibody or by Addition of the 
Cytokines 11.,2 or 11,I2.  Anti-hlL-10 antibody (0.5 mg per 
mouse) was administered as intraperitoneal injections (1.0 ml) 
24 h before tumor inoculation and on day 6  after inocula- 
tion. C57BL/6 mice were inoculated with 5  x  104 CL8-1- 
vlL-10 (81.1 ng/106 cells per 48 h) or nontransduced CL8-1 
cells on day 0 (Fig. 5, B and E). While 80% of animals inoc- 
ulated with CL8-1-vlD10 developed progressively growing 
tumors, CL8-1-vlbl0 cells failed to grow in animals receiving 
anti-hlL-10 antibody. The size of the CLS-I-vlL-10 tumors 
at day 28 (18.0  +  10.4 mm 2) was significantly larger than 
that  of  CLS-I-vlL-10  with  anti-vlL-10  antibody  (0  -+ 
0 mm 2, P  =  0.005).  Significant neutralization  of the vlL- 
10 effect was demonstrated with administration of anti-vlL- 
10 antibody. The growth of nontransduced CL8-1 tumor was 
not altered upon administration of anti-vlL-10 antibody. To 
examine whether  other cytokines could reverse the vlL-10 
effects, rhlL-2 (600,000 IU daily from day 7 to day 13) or 
rmlL-12 (0.1/zg daily from day 7 to day 13) was administered 
systemically (intraperitoneally) into C57BL/6 mice that re- 
ceived intradermal injection of 5  x  104 CL8-1-vlL-10 (67.3 
ng/106 cells per 48 h) or nontransduced CL8-1 cells on day 
0 (Fig. 5, C and F). All mice that received CL8-1-vlD10 cells 
developed palpable tumor within 10 d, while nontransduced 
CL8-1 tumors progressed in only 40-60%  of mice. In this 
experiment, the growth of CL8-1-vlL-10 tumors as well as 
of nontransduced CL8-1 tumors was significantly inhibited 
after systemic IL-2 or IL-12 administration.  In the rhlL-2-ad- 
ministered animals, the percentage of animals with palpable 
tumor  (20%)  and  the  tumor  area  (0.8  _+  1.8  mm  2, 
P  <0.0001) at day 35 were similar to those in the group ad- 
ministered rmlL-12 (0%,  0  -+  0  mm 2, P  <0.0001),  when 
compared with that of control or Hanks' solution-adminis- 
tered groups (38.2  +-  7.4 mm  2 or 37.6  +  3.2 ram2). Thus, 
systemic IL-12  or IL-2  administration  significantly reversed 
vlL-10-mediated suppression  of tumor rejection. 
Profound Differences Exist between vlL10 and mlblO in Im- 
munomodulatory Functions.  To analyze the differences between 
vlL-10 and raiL-10 in immunomodulatory functions, varying 
doses of nontransduced  CL8-1,  CL8-1-vlL-10 (56.5  ng/106 
cells per 48 h) and CL8-1-mlL-10 (51.0 rig/10  + cells per 48 h) 
cells were injected into C57BL/6 mice (Fig.  6, A  and B). 
When  1  x  104 cells were injected into  the animals,  60% 
of the animals with CLS-I-vlL-10 displayed palpable growing 
tumors, while tumor was identified in none of the animals 
receiving nontransduced CL8-1 or CL8-1-mlbl0. For the size 
of the  tumors  at  day 23,  values were  7.2  _+  6.6  mm  2 in 
CL8-1-vlL-10 tumors and 0  -+  0 mm  2 in both CL8-1-mlL- 
10 and nontransduced CL8-1 tumors, a statistically significant 
difference (P  =  0.04).  When  10  s cells were injected into 
animals,  100%  or 60%  of the animals  with CLS-I-vlL10 
cells or nontransduced CL8-1 cells developed palpable pro- 
gressively growing tumors, respectively. All animals receiving 
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Figure  6.  rill0  and  raiL-10 differ profoundly  in  their  tumor im- 
munomodulatory functions. C57BL/6 mice were inoculated intradermally 
in left flank with CL8-1-vIL-10,  CL8-1-mIIr  or nontransfected CL8-1 
cells (.4, 1  x  104; B, 1  ￿  10s).  (O) CL8-1-mIL10; (A) CL8-1-vIL-10; 
(iT) CL8-L 
the same dose of CL8-1-mlL-10 cells initially developed small 
palpable  tumors,  but  they were rejected  within  20  d.  The 
size  of the  CL8-1-mlL-10  tumors  at  day  23  (0  _+  0  mm  2) 
was  significantly  smaller  than  those  of CLS-I-vlL-10 (18.8 
+_  5.9  mm  2,  P  <0.0001)  or  nontransduced  CL8-1  tumors 
(8.8  _+  8.2  mm  z,  P=0.043).  These  results  indicated  that 
raiL-10,  unlike  vlL-10,  transduction  of CL8-1  significantly 
promoted  immune  rejection  of tumor. 
Immunohistological Evaluation of CLS-1,  CL8-1-vlL, IO, and 
CL8-1-mlblO  Tumors.  After  staining  of  nontransduced 
CL8-1, CL8-1-vlL-10, and CL8-1-mlL-10 tumors with mAbs 
to T  cell subsets, a specific cellular CD4 + and CD8 + T  cell 
infiltrate was identified.  Nontransduced  CL8-1 tumors were 
infiltrated  with  a  large  number  of CD4 §  and  a  moderate 
number of CD8 + lymphocytes (Fig.  7, A-C).  Conversely, 
only  a  few  CD4 +  and  CD8 +  lymphocytes were  observed 
within  CL8-1-vlL-10 tumors  (Fig.  7,  G-I).  CL8-1-mlL-10 
tumors  displayed  a  modest  number  of  both  CD4 +  and 
CD8 +  lymphocytes  (Fig.  7,  D-F).  Interestingly,  CD4 § 
and CD8 + lymphocytic infiltration  of CL8-1-vlL-10 tumor 
differs from the characteristic dense infiltration of CD4 + and 
CD8 §  lymphocytes surrounding  regressing  nontransduced 
CL8-1 or CL8-1-mlL-10.  Additionally,  CD8 + lymphocytes 
were observed primarily in the peritumoral  area of CL8-1- 
mlL-10 tumors and within the nontransduced CL8-1 tumors. 
Discussion 
We have constructed retroviral vectors that allow for high 
level secretion of vlL-10 and mlL-10 by transduced cells.  Using 
this vector system, we demonstrated that local vlL-10 secre- 
tion can inhibit  or suppress immune rejection of immuno- 
genic tumor cells in both syngeneic and allogeneic settings. 
The local secretion of vlL-10 does not affect the rejection of 
a nontransduced  tumor at a distant  site.  These results  sug- 
gest that the local secretion of vlL-10 protein does not have 
systemic effects but,  rather,  only local  immunosuppressive 
effects. We have also shown that vlL-10-transduced nontrans- 
formed fibroblasts,  when  admixed  with  tumor  cells,  yield 
similar immunosuppressive effects in vivo. Furthermore, when 
Figure  7,  Marked  differences  in the infiltration of T cells  into nontrans- 
fected CL8-1, CL8-1-vlL-10,  and CL8-1-mlbl0 tumors. To identify lym- 
phocyte subsets in the tumor infiltrations, tumor sections were obtained 
from animals 10 d after inoculation of tumor. These animals were evalu- 
ated using a panel of murine-specific  CD4 and CD8 antibodies. Nontrans- 
fected CL8-1 tumor was demonstrated to be infiltrated by large numbers 
of CD4 + (A) and moderate numbers of CD8 + lymphocytes (B, C). CL8- 
1-mlL-10 tumors also showed a moderate number of both CD4+ (1))  and 
CD8 + lymphocytes (E, F). The only immunological effect that we could 
detect by immunohistochemistry in CL8-1-vlL-10  tumors was infiltration 
by only a few CD4 + (G) and CD8 + lymphocytes  (/4, I) within the tumor 
CDS+ lymphocytes  were observed  mainly in the intratumoral area of non- 
transfected CL8-1 tumors (B) and in the pefitumoral area of CL8-1-mlId0 
tumors (F). Original  magnification: 50. 
vlL10-secreting fibroblasts are combined with vlL-10-secreting 
tumor  cells  and  inoculated  in  vivo,  the  extent  of the  im- 
munosuppression  is  greater  than  that  observed  with  vIL- 
10-secreting  tumor cells alone.  Thus,  the immunosuppres- 
sire  effects associated with  vIL-10 are dose dependent,  but 
independent  of the  source  of the  vIL-10. 
These vIL-10 effects were abrogated when anti-vlL-10 an- 
tibody or immunostimulatory cytokines, such as IL-2 and IL-12, 
were administered systemically to the tumor-bearing animals 
in vivo. This result suggests that vIL-10 protein  secreted by 
the tumor cells is responsible for this  observation and  that 
the mechanism of the vIL-10 immunosuppression might in- 
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NK cells to produce IFN-3' at high levels (30) and enhances 
primarily a Thl cellular immune response (31). IL-2 is a growth 
factor that stimulates the proliferation  of cytotoxic T cells, 
Th, and NK cells, and generates LAK activity (32-35). Thus, 
immunosuppressive  effects of vlL-10 might be mediated by 
inhibition of IL-12-associated  functions, including IFN-3~ in- 
duction, NK or Thl function and/or differentiation, and IL-2 
synthesis by cytotoxic  T cells. This interpretation is compat- 
ible with the previous findings observed with clL-10 in vitro. 
(1,  8,  9, 36-38). 
The effects of vlL-10 we have observed in vivo support the 
idea that vlLol0 has retained the CSIF or macrophage/dendritic 
cell-deactivating activities of clL-10. It has been suggested 
that the gene transfer of vlL-10 using our retroviral vectors 
prolonged cardiac allograft survival in a heterotopic, nonvas- 
cularized allograft model, and it has been demonstrated that, 
when allografts were transduced with vlL-10, decreased num- 
bers  of CD2 +-,  CD3 +-,  CD4 +-,  and  CD8+-expressing 
lymphocytes were observed (Qin, L., unpublished  observa- 
tion). Our immunohistochemical results also showed that 
infiltration  by CD4 + and CD8 + lymphocytes in animals 
bearing CL8-1-vlL-10 tumors was markedly reduced compared 
with that in nontransduced CL8-1 or CLS-I-mlL-10 tumors. 
These observations are consistent with the notion that h- and 
vlL-10 block the Ag-specific proliferation of  both total T cells 
and CD4 + Thl- or Th2-1ike T  cell clones (10). However, 
the in vivo effect of mlL-10 expression by the same tumor 
cells was, surprisingly,  to stimulate rejection of the tumor. 
clL-10 has additional  activities, such as costimulation of T 
cell/thymocyte growth and differentiation (11, 39, 40), chemo- 
tactic effects on CD8 cells (41), and induction of adhesion 
molecule expression by endothelial cells (42), which vlL-10 
may lack (11, 39). 
Recent studies by others (42, 43) also suggest that clbl0 
may have complex effects in vivo. The expression of clL-10 
under control of the insulin promoter in transgenic mice is 
associated with pronounced pancreatic inflammation, domi- 
nated by the presence of CD4 + and CD8 + T  cells and B 
lymphocytes. The exocrine tissue is completely destroyed, but 
the islets of Langerhans are intact and appear to function nor- 
mally (42). In nonobese diabetic mice, production of IL-10 
by islet cells markedly accelerated immune-mediated  destruc- 
tion of 3  cells (43). In contrast, systemic administration of 
clL-10 blocked the onset of  diabetes in nonobese diabetic mice 
(44). Thus, our results, along with those of Wogensen and 
co-workers,  suggest that stimulatory effects of clL-t0 on T 
cells and other cells may obscure the consequences of  its "sup- 
pressive" effects on the APC and accessory cell functions of 
macrophages and dendritic cells when clL-10 is expressed lo- 
cally at high levels. Our studies with systemic administra- 
tion of hlL-10 (Berman,  R.,  T.  Suzuki,  H.  Tahara, S.  K. 
Narula, P. D. Robbins, and M. T. Lotze, manuscript sub- 
mitted for publication) suggest that it has significant immuno- 
stimulatory functions, promoting the rejection of established 
day 7 murine tumors when high doses (higher than 20 #g 
per mouse) are administered  daily for 7 d. 
The basis for the apparent differences in clL-10 and vlL-10 
activities is only partially understood, cDNA clones encoding 
mouse and hlL-10R ligand-binding chains have been isolated 
and characterized (45, 46). Both rlL-10R bind their respec- 
tive clbl0 ligand with high affinity yet exhibit at least a 100- 
fold lower affinity for vlL-10 than for clL-I0 (46a). Neverthe- 
less, vlL-10 stimulates proliferation  of mlL-10R-transduced 
Ba/F3 cells with a specific  activity only 3-10-fold lower than 
clL-10, as is observed on normal cells that respond to both 
clbl0 and vlL-10 (46a). These and other observations (Moore, 
K. W., unpublished  observations) support  the notion that 
IL-10R expression on vlL-10-responsive cells is composed of 
the ligand-binding  (c~) chain that binds,  and one or more 
additional components that are required for interaction with 
vlL-10. Further studies of IL-10R structure should clarify the 
nature of the vlL-10 "defect:' 
The immunosuppressive effects of locally expressed vlL-10 
suggest the possible application of vlL-10 in allogeneic organ 
transplantation.  Although organ transplantation is now rec- 
ognized as an established life-saving measure for various dis- 
eases (47), most patients who receive organ or cellular trans- 
plantation require systemic immunosuppression  for the rest 
of their lives using cyclosporin A or FKS06 (48). During the 
prolonged period of general immunosuppression, patients are 
susceptible to opportunistic infections and malignancies. In 
theory, if local immunosuppression  similar to that observed 
in this study could be achieved at the site of the transplanted 
organ by gene transfer, immune rejection of the graft could 
be blocked without disturbing systemic immune function. 
In contrast to vlL-10, our results with clL-10 suggest that 
it could be developed as an antitumor reagent when used in 
a gene therapy strategy. The possibility of using clL-10 as 
an antitumor agent in gene therapy has been reported by 
Richter et al. (49) using mlbl0-transduced Chinese ham- 
ster ovary (CHO) cells. CHO-IL-10 cells grew normally in 
vitro but did not grow as tumors in immunodeficient animals 
(either nude or SCID mice). This effect was IL-10 dose-de- 
pendent, and CHO-IL-10 cells also suppressed the growth 
of tumors if coinjected with nontransduced CHO cells. Im- 
munohistologic examination suggested that raiL-10 inhibited 
the infiltration of macrophages that was observed for tumors 
containing nontransduced CHO cells. Although direct in- 
terpretations  of these results are limited because of the na- 
ture of the tumor selected and the use of immunodeficient 
animals, they suggest that, under certain circumstances, clL- 
10 can stimulate an immune response (Velu, T., and G. Forni, 
personal communication). Consistent with these results, we 
have shown that establishment of CL8-1 melanoma cells (Fig. 
6), MC38 colon cancer cells, and MCA102 fibrosarcoma cells 
can  be  abrogated  in  syngeneic,  immunocompetent mice 
(C57BL/6) (data not shown). We have also shown that the 
abrogation  of tumor establishment leads to the promotion 
of protective immunity to a subsequent challenge with non- 
transduced  tumor cells. Therapeutic effects are now being 
tested to examine the potential  clinical application of this 
strategy. The discordant in vivo effects observed when com- 
paring vlL-10 and mlL-10 should be noted for further charac- 
terization  of these cytokines with multiple functions. We thank Dr. T. Itoh for helpful suggestions, Dr. W. J. Storkus for careful review of the manuscript, 
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